Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003063009 | SCV003450563 | uncertain significance | Noonan syndrome | 2022-09-14 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals affected with RRAS-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0008%). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 70 of the RRAS protein (p.Cys70Tyr). |
Ambry Genetics | RCV004070343 | SCV004088627 | uncertain significance | not specified | 2023-06-22 | criteria provided, single submitter | clinical testing | The p.C70Y variant (also known as c.209G>A), located in coding exon 2 of the RRAS gene, results from a G to A substitution at nucleotide position 209. The cysteine at codon 70 is replaced by tyrosine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |